Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 02, 2023

SELL
$0.12 - $0.23 $900 - $1,725
-7,500 Reduced 33.33%
15,000 $2,000
Q4 2022

Jan 17, 2023

SELL
$0.09 - $0.2 $675 - $1,500
-7,500 Reduced 25.0%
22,500 $0
Q3 2022

Oct 12, 2022

BUY
$0.15 - $3.02 $4,500 - $90,600
30,000 New
30,000 $5,000

Others Institutions Holding HGEN

About HUMANIGEN, INC


  • Ticker HGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,661,000
  • Description
  • Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...
More about HGEN
Track This Portfolio

Track Wealth Alliance Advisory Group, LLC Portfolio

Follow Wealth Alliance Advisory Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wealth Alliance Advisory Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wealth Alliance Advisory Group, LLC with notifications on news.